Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D Status, Cognitive Decline and Dementia Associations: Study Summary

Previous related pageVitamin D Status, Cognitive Decline and Dementia Associations: Full StudyNext related pageVitamin D Status, Cognitive Decline and Dementia Associations: Full Study
Study at a glance

What did studies compare about vitamin D, thinking skills and dementia?

This page compares studies of vitamin D blood levels and later dementia or changes in thinking skills with trials of vitamin D3 supplements. Observing a link between a low blood level and later illness is different from showing that treatment prevents the illness. The studies also measured different outcomes, including new dementia diagnoses and performance on memory and planning tests.

Were low vitamin D levels linked with dementia or declining thinking skills?

A study of 1,658 older adults initially without dementia found a higher rate of later dementia in people with lower vitamin D. Another study found faster decline in memory and planning skills in lower-vitamin-D groups, but not in every area tested. These findings could partly reflect other health and lifestyle differences. Early disease may also change diet or outdoor activity before diagnosis, lowering vitamin D.

Did vitamin D supplements slow declining thinking skills?

A trial called VITAL did not show an overall slowing of decline in thinking skills with vitamin D3 over about two to three years. Its two assessment groups came from one trial, not two independent trials. A favourable subgroup finding needed confirmation. Another trial, called VitaMIND, also reported no significant overall benefit for thinking skills over two years. People qualified for the study as having low vitamin D based on a questionnaire, with blood confirmation available only for a small subgroup.

What remains uncertain about vitamin D and dementia prevention?

Missing later assessments and limited evidence in people with severe deficiency restrict how widely the trial findings apply. Possible biological explanations were not proven by these human studies. Low vitamin D may be a useful sign of risk to investigate, but these results do not establish a blood target, supplement dose or proven way to prevent dementia.

Read the full article below ↓

Lower blood vitamin D has been associated with later dementia and faster decline in some cognitive abilities. Those associations do not establish that supplements prevent either outcome. Randomised trials provide an important check on that interpretation. For the detailed evidence and limitations, read Vitamin D Status, Cognitive Decline and Dementia Associations: Full Study.

What the observational studies found

Littlejohns and colleagues followed 1,658 older adults who initially had no dementia, stroke or cardiovascular disease. Lower baseline vitamin D categories were associated with a higher rate of later dementia. The lowest category had a fully adjusted hazard ratio of 2.25 compared with the highest category, with a wide confidence interval. This relative rate is not an individual probability or an expected treatment benefit.

Miller and colleagues followed a multiethnic cohort with repeated cognitive tests. Lower vitamin D categories were associated with faster decline in episodic memory, the ability to recall experiences, and executive function, which supports planning and switching tasks, but not every measured domain. The population included people with differing cognitive status at entry. The studies therefore address related but distinct questions within the brain evidence.

Why association does not establish prevention

Low vitamin D can accompany changes in health, diet and outdoor activity. Early disease may influence these factors before a diagnosis is recorded. Statistical adjustment and exclusion of early diagnoses help, but cannot remove every source of confounding or reverse causation. The cohorts also used different vitamin D categories and cognitive outcomes.

What supplementation trials add

The VITAL cognitive study tested 2,000 international units of vitamin D3 daily against placebo in two subsets of one parent trial. It did not demonstrate an overall slowing of cognitive decline over approximately two to three years. A favourable subgroup finding required cautious interpretation and replication. The two subsets are not two independent trials.

The 2025 VitaMIND trial likewise reported no significant overall cognitive benefit over twenty-four months. Its low-status eligibility was predicted by questionnaire; blood confirmation was available only in a small subgroup. Substantial missing follow-up data and limited representation of severe deficiency restrict generalisation. The tested doses do not become recommendations for readers.

What remains uncertain

The neighbouring concepts of neuroendocrine integration and inflammatory signalling provide possible biological explanations, but these human studies did not prove those mechanisms. A plausible pathway cannot substitute for a demonstrated clinical effect.

The evidence supports studying low vitamin D as a risk marker. It does not establish a blood target, supplement dose or proven method of preventing dementia. Better evidence requires clearly defined populations, confirmed exposure, sustained follow-up and meaningful cognitive outcomes. Unavailable supplementary cohort and prediction-model material was not treated as independently verified.

Scientific sources

Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83:920 to 928. DOI:10.1212/WNL.0000000000000755. PMID:25098535. Complete principal paper, two figures and three tables examined; supplementary tables were inaccessible.

Miller JW, Harvey DJ, Beckett LA, et al. Vitamin D Status and Rates of Cognitive Decline in a Multiethnic Cohort of Older Adults. JAMA Neurology. 2015;72:1295 to 1303. DOI:10.1001/jamaneurol.2015.2115. PMID:26366714. Complete principal paper, trajectory figure and four tables examined; supplemental table was inaccessible.

Kang JH, Vyas CM, Okereke OI, et al. Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. Scientific Reports. 2021;11:23253. DOI:10.1038/s41598-021-02485-8. PMID:34853363. Complete principal paper, main figure, six tables and eight-page supplementary appendix examined. A validation plot cited in the appendix was not present in the retrieved file.

Corbett A, Taylor R, Llewellyn D, et al. Impact of Vitamin D Supplementation on Cognition in Adults With Mild to Moderate Vitamin D Deficiency: Outcomes From the VitaMIND Randomized Controlled Trial. Journal of the American Medical Directors Association. 2025;26:105711. DOI:10.1016/j.jamda.2025.105711. PMID:40480279. Complete principal-report text and tabulated outcomes read; supplementary prediction material was inaccessible. Used as bounded supporting evidence.

Related reading

Original sources

Source

Vitamin D and the risk of dementia and Alzheimer disease

Published in Neurology (2014).

Publication details

Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83:920 to 928. DOI:10.1212/WNL.0000000000000755. PMID:25098535. Complete principal paper, two figures and three tables examined; supplementary tables were inaccessible.

Read more →
Source

Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial

Published in Scientific Reports (2021).

Publication details

Kang JH, Vyas CM, Okereke OI, et al. Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. Scientific Reports. 2021;11:23253. DOI:10.1038/s41598-021-02485-8. PMID:34853363. Complete principal paper, main figure, six tables and eight-page supplementary appendix examined. A validation plot cited in the appendix was not present in the retrieved file.

Read more →
Source

Impact of Vitamin D Supplementation on Cognition in Adults With Mild to Moderate Vitamin D Deficiency: Outcomes From the VitaMIND Randomized Controlled Trial

Published in Journal of the American Medical Directors Association (2025).

Publication details

Corbett A, Taylor R, Llewellyn D, et al. Impact of Vitamin D Supplementation on Cognition in Adults With Mild to Moderate Vitamin D Deficiency: Outcomes From the VitaMIND Randomized Controlled Trial. Journal of the American Medical Directors Association. 2025;26:105711. DOI:10.1016/j.jamda.2025.105711. PMID:40480279. Complete principal-report text and tabulated outcomes read; supplementary prediction material was inaccessible. Used as bounded supporting evidence.

Read more →